Currently Viewing:
Currently Reading
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

Treg Cells Continue Suppressing Immunotherapy Even After They Are Eliminated

Alison Rodriguez
New research shows that eliminating Treg cells that prevent the cancer-fighting effect of an immunotherapy treatment doesn't actually end their suppressive qualities. 
Treg cell activity suppresses the immune response and therefore stops the cancer-fighting effect of the immunotherapy treatments; however, eliminating the Treg cells does not end their suppressive qualities, according to new research.

In a study recently published in Nature Immunology, researchers investigated the effects of immune cell activity that may limit immunotherapy’s effectiveness. T cells fight the infection and Treg cells send the signal to the T cells to stop fighting the threat. Immunotherapies super-charge the immune system to fight the cancer, and when the Tregs come in to suppress the immune response, they also stop the cancer-fighting effect.

The researchers found that eliminating the Treg cells does not provide any benefits to patients and does not eliminate their suppressive qualities, because when the Tregs die they become more suppressive rather than negated.

The study found that when the Treg cells die they release small metabolites called ATP, which help supply energy to the body. The dying Tregs quickly convert the ATP to adenosine which then targets the T-cells—this makes the T cells unhealthy and negatively affects how they function, the study found.

“It’s a double-edged sword: If they do not die, they are suppressive. But if they die, they are even more suppressive,” senior study author Weiping Zou, MD, PhD, Charles B. de Nancrede Professor of surgery, immunology, pathology and cancer biology at the University of Michigan, said in a statement. “Nobody expected this – it was a total surprise. But it likely explains why you don’t see benefit when you induce Treg apoptosis."

Although immunotherapy has demonstrated many benefits and revolutionized cancer treatment, there remains to be many limitations and unanswered questions. The researchers are now looking to limit the negative function of Treg cells by forming a roadblock to stop the cells from migrating to the tumor microenvironment in addition to controlling the suppressive activity.

Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!